跳至主導覽
跳至搜尋
跳過主要內容
國立成功大學 首頁
English
中文
首頁
概要
研究單位
研究成果
專案
學生論文
設備
獎項
活動
按專業知識、姓名或所屬機構搜尋
查看斯高帕斯 (Scopus) 概要
張 定宗
教授
內科學科
電話
886 6 2353535 ext 5405 or 5389
電子郵件
ttchang
mail.ncku.edu
tw
網站
http://imm.med.ncku.edu.tw/e_website/faculty/Faculty_english/ttc_e.htm
h-index
18821
引文
55
h-指數
按照存儲在普爾（Pure）的出版物數量及斯高帕斯（Scopus）引文計算。
1988 …
2025
每年研究成果
概覽
指紋
網路
專案
(40)
研究成果
(234)
類似的個人檔案
(8)
監製作品
(5)
指紋
查看啟用 Ting-Tsung Chang 的研究主題。這些主題標籤來自此人的作品。共同形成了獨特的指紋。
排序方式
重量
按字母排序
Pharmacology, Toxicology and Pharmaceutical Science
Chronic Hepatitis B
100%
Hepatitis B Virus
94%
Liver Cell Carcinoma
76%
Hepatitis B(e) Antigen
59%
Hepatitis B
55%
Entecavir
54%
Lamivudine
38%
Hepatitis C Virus
37%
Hepatitis B Antigen
35%
Chronic Hepatitis C
32%
Virus DNA
30%
Hepatitis C
30%
Alanine Aminotransferase
29%
Liver Cirrhosis
24%
Antiviral Therapy
19%
Adefovir Dipivoxil
19%
Ribavirin
18%
Chronic Hepatitis
15%
Infection
14%
Placebo
13%
Interferon
13%
Antiviral Drug
12%
Tenofovir Disoproxil
10%
Ledipasvir Plus Sofosbuvir
10%
Prevalence
10%
Combination Therapy
10%
Fibrosis
9%
Antivirus Agent
9%
Programmed Death 1 Receptor
8%
Virus RNA
8%
Biological Marker
8%
Ascites
8%
Immune Checkpoint Inhibitor
8%
Adverse Event
8%
Virus Infection
8%
Liver Injury
8%
Recurrent Disease
7%
Peginterferon
7%
Toxic Hepatitis
7%
Peginterferon Alpha2a
7%
Hepatitis G Virus
7%
Tenofovir Alafenamide
7%
Pharmacokinetic
7%
Sorafenib
7%
Diseases
6%
Non Insulin Dependent Diabetes Mellitus
6%
Nucleoside
6%
Clinical Trial
6%
Membrane Antigen
5%
Liver Disease
5%
Medicine and Dentistry
Hepatocellular Carcinoma
80%
Hepatitis B Virus
29%
Chronic Hepatitis B
27%
Liver Cirrhosis
20%
Hepatitis B(e) Antigen
19%
Hepatitis B
17%
Chronic Hepatitis C
17%
Hepatitis C Virus
15%
Hepatitis C
15%
Neoplasm
14%
Hepatitis B Antigen
12%
Alanine Aminotransferase
12%
Ribavirin
12%
Lamivudine
11%
Recurrent Disease
11%
Entecavir
11%
Maturity Onset Diabetes of the Young
10%
Infection
9%
Hazard Ratio
9%
Seroconversion
9%
Immune Checkpoint Inhibitor
8%
Peginterferon
8%
Bleeding
7%
Antiviral Therapy
7%
Esophageal Varices
7%
Antiviral Drug
7%
Diabetes
7%
Pembrolizumab
7%
Arterial Embolization
7%
Polypeptide
7%
Antigen Specificity
7%
Caroli Disease
7%
Ledipasvir Plus Sofosbuvir
7%
Ligation
7%
Multivariate Analysis
6%
Tumor Thrombus
6%
Hepatitis Virus
6%
Virus DNA
6%
Portal Venous Pressure
5%
Cancer Staging
5%
Overall Survival
5%
Malignant Neoplasm
5%
Prognostic Factor
5%
Cumulative Incidence
5%
Venous Pressure
5%
Platelet
5%
Keyphrases
Hepatitis B Surface Antigen (HBsAg)
18%
Hepatitis C Virus
16%
Hepatitis C
15%
Chronic Hepatitis C
15%
Taiwan
15%
Entecavir
14%
Hepatocellular Carcinoma
13%
Hepatitis B e Antigen (HBeAg)
13%
Sustained Virological Response
12%
Hepatitis B Virus
11%
Hepatitis C Virus Infection
11%
Hepatitis C Virus RNA
11%
Hepatitis B
10%
Ledipasvir
10%
Chronic Hepatitis B
10%
Type 2 Diabetes Mellitus (T2DM)
10%
Anti-hepatitis C Virus
8%
Ascites
7%
Ropeginterferon alfa-2b
7%
Ribavirin
7%
Lamivudine
7%
Peripheral Blood Mononuclear Cells
7%
Gray Zone
7%
Adefovir Dipivoxil
7%
High-dose Interferon
7%
Competitive PCR
7%
End of Treatment
6%
Hepatitis B Virus DNA
5%
B Hepatitis
5%
Combination Therapy
5%
Confidence Interval
5%
